Focus: MicroTransponder is a public biotech company developing vagus nerve stimulation (VNS) devices for neurological and cardiovascular indications, with primary focus on stroke recovery and spinal cord injury rehabilitation.
Profile data last refreshed 14h ago · AI intelligence enriched 3w ago
No open roles listed right now. Follow MicroTransponder to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for MicroTransponder
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from MicroTransponder's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
RxERP Integrates Embedded Microtransponder Technology for Improved Pharmaceutical Traceability - ERP Today
RxERP Integrates Embedded Microtransponder Technology for Improved Pharmaceutical Traceability ERP Today
RxERP and p‑Chip Corporation Announce Licensing Agreement to Enable Embedded Unit‑Level Digital Identity for DSCSA Compliance and End‑to‑End Pharmaceutical Traceability - Business Wire
RxERP and p‑Chip Corporation Announce Licensing Agreement to Enable Embedded Unit‑Level Digital Identity for DSCSA Compliance and End‑to‑End Pharmaceutical Traceability Business Wire
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications